Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viral Transfer Technology
  • Published:

Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers

Abstract

One of the current challenges in gene therapy is to construct a vector that will target specific tissues. Targeting expression to endothelium is of particular interest in the treatment of several pathologies. We have shown previously that defined regions of the E-selectin and KDR promoters confer endothelial cell specific expression following retroviral delivery. However, the levels of expression were low. In an attempt to increase expression but to preserve the tissue specificity we have examined hypoxic and cytokine-inducible enhancer elements in combination with the KDR and E-selectin promoters. Both enhancers should be active in the tumour environment, boosting expression and giving additional specificity of gene expression in the tumour endothelium. The hypoxia response element (HRE) of the murine phosphoglycerate kinase-1 (PGK-1) promoter was used as a hypoxic enhancer and the tandem-binding site for NFκB from the murine vascular cell adhesion molecule-1 (VCAM-1) promoter as a cytokine-inducible enhancer. The HRE conferred hypoxia inducibility to the KDR and E-selectin promoters. Endothelial specificity of expression was retained with the KDR but not the E-selectin promoter. The NFκB-binding site conferred responsiveness to TNF-α to the KDR promoter, however the level of induction was less than that achieved with the HRE. Retrovirus combining both enhancer elements transferred inducibility by hypoxia and TNF-α, and reached the highest expression levels upon stimulation. These results confirm that heterologous enhancer elements may operate on a single endothelial cell specific promoter. These findings make the use of inducible enhancers a promising strategy for increasing tissue specific gene expression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Jaggar RT et al. Endothelial cell-specific expression of tumor necrosis factor-a from the KDR or E-selectin promoters following retroviral delivery Hum Gene Ther 1997 8: 2239–2247

    Article  CAS  PubMed  Google Scholar 

  2. Quinn TP et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium Proc Natl Acad Sci USA 1993 90: 7533–7537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bevilacqua MP et al. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins Science 1989 243: 1160–1165

    Article  CAS  PubMed  Google Scholar 

  4. Brown LF et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer Hum Pathol 1995 26: 86–91

    Article  CAS  PubMed  Google Scholar 

  5. Kraling BM et al. E-selectin is present in proliferating endothelial cells in human hemangiomas Am J Pathol 1996 148: 1181–1191

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Fox SB et al. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium J Pathol 1995 177: 369–376

    Article  CAS  PubMed  Google Scholar 

  7. Vaupel PW . Oxygenation of solid tumors. In: BA Teicher (ed.) Drug Resistance in Oncology Marcel Decker: New York 1993 53–85

    Google Scholar 

  8. Wang GL et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proc Natl Acad Sci USA 1995 92: 5510–5514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dachs GU et al. Targeting gene expression to hypoxic tumor cells Nature Med 1997 3: 515–520

    Article  CAS  PubMed  Google Scholar 

  10. Maxwell PH et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc Natl Acad Sci USA 1997 94: 8104–8109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Maxwell PH et al. The tumour supressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolyses Nature 1999 399: 271–275

    Article  CAS  PubMed  Google Scholar 

  12. Firth JD et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer Proc Natl Acad Sci USA 1994 91: 6496–6500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer Gene Therapy 1999 6: 1721–1727

    Article  CAS  PubMed  Google Scholar 

  14. Collins T et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers FASEB J 1995 9: 899–910

    Article  CAS  PubMed  Google Scholar 

  15. Tian H, Mcknight SL, Russell DW . Endothelial pas domain protein 1 (Epas1), a transcription factor selectively expressed in endothelial cells Gene Dev 1997 11: 72–82

    Article  CAS  PubMed  Google Scholar 

  16. Wiesener MS et al. Induction of endothelial Pas domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha Blood 1998 92: 2260–2268

    CAS  PubMed  Google Scholar 

  17. Boyle EMJ et al. Transcriptional arrest of the human E-selectin gene J Surg Res 1999 82: 194–200

    Article  CAS  PubMed  Google Scholar 

  18. Gerber H-P et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes J Biol Chem 1997 272: 23659–23667

    Article  CAS  PubMed  Google Scholar 

  19. Yin LY et al. Genomic structure of the human KDR/flk-1 gene Mamm Genome 1998 9: 408–410

    Article  CAS  PubMed  Google Scholar 

  20. Hata Y et al. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence J Biol Chem 1998 273: 19294–19303

    Article  CAS  PubMed  Google Scholar 

  21. Kappel A et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice Blood 1999 93: 4284–4292

    CAS  PubMed  Google Scholar 

  22. Patterson C et al. Nuclear protein interactions with the human KDR/Flk-1 promoter in vivo. Regulation of Sp1 binding is associated with cell type-specific expression J Biol Chem 1997 272: 8410–8416

    Article  CAS  PubMed  Google Scholar 

  23. Giraudo E et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells J Biol Chem 1998 273: 22128–22135

    Article  CAS  PubMed  Google Scholar 

  24. Patterson C et al. Down-regulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells J Clin Invest 1996 98: 490–496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Williams RL, Courtneidge SA, Wagner EF . Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene Cell 1988 52: 121–131

    Article  CAS  PubMed  Google Scholar 

  26. Markowitz D, Goff S, Bank A . Construction and use of a safe and efficient amphotropic packaging cell line Virology 1988 167: 400–406

    Article  CAS  PubMed  Google Scholar 

  27. Pepper MS et al. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells Exp Cell Res 1994 210: 298–305

    Article  CAS  PubMed  Google Scholar 

  28. McCarthy SA, Bicknell R . Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor beta 1. No evidence for pertussis-sensitive G-protein involvement in TGF-beta signal transduction J Biol Chem 1992 267: 21617–21622

    CAS  PubMed  Google Scholar 

  29. Morgenstern JP, Land H . Advanced mammalian gene transfer: high titre vectors with multiple drug selection markers and a complementary helper-free packaging cell line Nucleic Acids Res 1990 18: 3587–3596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yu SF et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells Proc Natl Acad Sci USA 1986 83: 3194–3198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Dr Martin K Oehler of the Angiogenesis Laboratory for helpful discussions, especially concerning statistical analysis of data. This work was funded by the Imperial Cancer Research Fund. CWP thanks the Medical Research Council (UK) for financial support.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Modlich, U., Pugh, C. & Bicknell, R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 7, 896–902 (2000). https://doi.org/10.1038/sj.gt.3301177

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301177

Keywords

This article is cited by

Search

Quick links